China Dry Age-Related Macular Degeneration (AMD) Market Research Report By Stage (Early Age-Related Macular Degeneration, Intermediate Age-Related Macular Degeneration, Late Age-Related Macular Degeneration), By Age Group (Above 75 years, Above 60 years, Above 40 years), By Diagnosis and Treatment (Treatment, Diagnosis), By Route of Administration (Oral, Injectables) and By End Users (Hospitals Clinics, Diagnostic Centers, Academic Research Institutes) - Forecast to 2035

China Dry Age-Related Macular Degeneration (AMD) Market Overview

As per MRFR analysis, the China Dry Age-Related Macular Degeneration (AMD) Market Size was estimated at 330.0 (USD Million) in 2023. The China Dry Age-Related Macular Degeneration (AMD) Market Industry is expected to grow from 360.0(USD Million) in 2024 to 910.0 (USD Million) by 2035. The China Dry Age-Related Macular Degeneration (AMD) Market CAGR (growth rate) is expected to be around 8.796% during the forecast period (2025 - 2035).

Key China Dry Age-Related Macular Degeneration (AMD) Market Trends Highlighted

The China Dry Age-Related Macular Degeneration (AMD) Market is witnessing noteworthy trends driven by an aging population and increased awareness about eye health. With the Chinese population aging rapidly, there is a growing demand for effective treatments and preventative measures against AMD. The government’s healthcare initiatives are prioritizing eye care, reflecting a commitment to combat vision impairment as part of its broader public health strategy. This focus is supported by campaigns aimed at educating citizens about AMD risk factors and the importance of regular eye check-ups, thus amplifying the emphasis on early diagnosis and intervention.

The market also has new opportunities resulting from improving technologies and the advancement of pharmaceuticals. There is a market opportunity in the development of new treatment alternatives, such as gene therapy or nutritional supplements. Domestic companies are now more willing to work with foreign partners in devising suitable therapeutics for the Chinese population which further deepens the market. Improving the distribution channels of ocular health products also helps these people receive the treatment they need. There is more interest in using telemedicine and online consultations for AMD patients in China because of the pandemic.

This shift not only ensures continued patient care but also addresses barriers to access, particularly in rural areas where specialized eye care services may be limited. As hospitals and clinics adapt to this digital shift, there will be further integration of e-health solutions in managing AMD. Overall, the convergence of technological innovation, government support, and increased public awareness is shaping a dynamic landscape for the Dry AMD market in China.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

China Dry Age-Related Macular Degeneration (AMD) Market Drivers

Aging Population in China Driving Market Growth

The aging population in China is a significant driver for the China Dry Age-Related Macular Degeneration (AMD) Market Industry. According to China's National Bureau of Statistics, in 2020, nearly 18% of the population was aged 60 or older, a figure expected to rise to over 34% by 2050. This demographic shift will lead to a higher prevalence of age-related diseases, including AMD, prompting increased demand for treatment options, screening procedures, and healthcare services.The growing elderly demographic will likely boost market investments from healthcare providers who need to cater to this expanding patient base. Additionally, the Ministry of Health has highlighted that the Chinese healthcare system is gearing up to manage chronic diseases tied to aging, which will further facilitate advancements and availability in the AMD market. The increasing number of elderly patients will ultimately necessitate more effective management strategies and products catered specifically for AMD.

Enhancements in Healthcare Infrastructure

Improvements in healthcare infrastructure significantly contribute to the growth of the China Dry Age-Related Macular Degeneration (AMD) Market Industry. The Chinese government has made substantial investments to enhance healthcare facilities across the nation, especially with the Healthy China 2030 plan. The plan emphasizes enhancing accessibility to medical services, which includes regular screening and early detection of age-related diseases like AMD.Over the last five years, there has been a reported 15% increase in the number of eye care clinics and hospitals due to government initiatives and support. This expansion means that more patients will have access to essential AMD treatment options, thereby increasing the market's reach and promoting customer engagement with healthcare services specifically designed to combat AMD.

Growing Awareness and Education on AMD

The increasing awareness and education about age-related eye diseases, specifically AMD, have become a critical driver for growth in the China Dry Age-Related Macular Degeneration (AMD) Market Industry. The Chinese government has launched numerous public health campaigns in collaboration with organizations such as the China Association of Ophthalmology, raising awareness about the risk factors and symptoms related to AMD. Reports from public health studies indicate that public awareness of AMD has doubled in the last decade, with over 60% of people now recognizing the condition and its related risks.As a result, more individuals are likely to seek preventive care and screening, leading to increased demand for AMD-targeted treatments and diagnostic services, ultimately benefiting the market's growth.

Innovation in AMD Treatments and Technologies

Ongoing innovation in treatments and technologies for AMD presents a compelling growth driver for the China Dry Age-Related Macular Degeneration (AMD) Market Industry. Recent advancements in pharmacological treatments, particularly the development of intravitreal injections and novel therapeutics, are sharpening their competitive edge in the medical field. The National Medical Products Administration in China has indicated a 25% increase in the approval of new ocular therapeutics over the past three years, reflecting the rapid progression in this domain.As new-generation drugs, such as anti-VEGF therapies, become more accessible and effective, healthcare providers are likely to adopt these technologies more widely, thus increasing patient treatment options and further driving market growth.

China Dry Age-Related Macular Degeneration (AMD) Market Segment Insights

Dry Age-Related Macular Degeneration (AMD) Market Stage Insights

The China Dry Age-Related Macular Degeneration (AMD) Market, classified into the stage of disease progression, reflects a critical aspect of combating vision-related issues prevalent among the aging population in the country. This market is structured into early, intermediate, and late age-related macular degeneration stages, which collectively represent different degrees of severity and clinical intervention requirements. 

The early stage serves as a precursor for potential vision loss, highlighting the importance of timely screening and detection in order to implement preventive measures or lifestyle modifications.As individuals progress to the intermediate stage, the condition may lead to noticeable vision changes, thus increasing demand for targeted therapies and management strategies tailored to those affected. The late stage, characterized by significant vision impairment, is crucial for healthcare systems, requiring advanced treatment options and possibly surgical interventions to improve patient outcomes. 

With a growing elderly demographic in China, the emphasis on understanding each progression stage of Dry AMD is paramount for healthcare professionals.As a result, healthcare providers are investing in education and awareness campaigns aimed at early detection, fostering greater engagement among at-risk populations. Moreover, government health policies are increasingly focusing on funding for research and development initiatives that explore new therapeutic options and enhance patient access to necessary care. 

The increasing prevalence of risk factors such as obesity and smoking further drives the importance of addressing this condition within the healthcare framework. The rising awareness around early detection and management of varying stages of AMD is anticipated to contribute significantly to the growth of the China Dry Age-Related Macular Degeneration (AMD) Market, reflecting a crucial area of interest for industry stakeholders.The complexity of managing these diverse stages presents opportunities for innovative solutions aimed at minimizing the burden of this chronic condition and enhancing the quality of life for the affected individuals. 

Thus, understanding the nuanced characteristics of each stage within Dry AMD is essential for delineating market trends and fortifying approaches tailored to the needs of China's aging population.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Dry Age-Related Macular Degeneration (AMD) Market Age Group Insights

The China Dry Age-Related Macular Degeneration (AMD) Market showcases significant segmentation by age group, reflecting the critical demographics influenced by this condition. The elderly population, particularly those above 75 years, represents a substantial portion of the affected demographic, owing to the natural progression of age-related health issues. This age group often experiences heightened exposure to health risks that lead to the development of AMD, thus creating a significant demand for treatment and management solutions. 

Meanwhile, individuals above 60 years are witnessing increasing incidences of AMD as longevity improves, further driving the need for adequate healthcare resources and awareness.Additionally, the group above 40 years is emerging as a focal point of concern, as early signs of AMD can manifest, stressing the importance of early detection and preventive measures. The growth drivers in these segments include an aging population, enhanced healthcare accessibility, and advancement in diagnostic technologies. Challenges arise from the need for tailored treatment approaches to cater to diverse age-related health statuses. 

This multifaceted approach to market segmentation underscores the market's evolution in addressing AMD across different age demographics, aligning efforts to improve patient outcomes and awareness in China’s healthcare landscape.

Dry Age-Related Macular Degeneration (AMD) Market Diagnosis and Treatment Insights

The Diagnosis and Treatment segment of the China Dry Age-Related Macular Degeneration (AMD) Market plays a crucial role in mitigating the effects of the disease that significantly impacts the aging population. As the prevalence of AMD rises in China due to an increasingly aging demographic, the demand for effective diagnostic tools and innovative treatment options is on the rise. The growing awareness about early detection and management of AMD has driven improvements in diagnostic technologies, allowing for timely interventions that can enhance the quality of life of patients.Treatments mainly focus on slowing disease progression and improving retinal health, which is essential given the potential vision impairment associated with AMD. 

Furthermore, the expanse of the healthcare ecosystem in China is seeing significant investments directed towards advancements in both diagnosis and treatment methods, aligning with the global trend towards innovation in ophthalmology. This focus not only addresses the current healthcare needs but also aims to improve patient outcomes in a market expected to grow substantially as China navigates its demographic shifts.The integration of digital health technologies also represents an opportunity for enhancing patient management and outcomes within this segment.

Dry Age-Related Macular Degeneration (AMD) Market Route of Administration Insights

The Route of Administration segment within the China Dry Age-Related Macular Degeneration (AMD) Market plays a crucial role in the overall management and treatment of this condition. This market segment is primarily characterized by two main forms: oral formulations and injectables. Oral medications offer a convenient method for patients, facilitating easier ingestion, which is especially beneficial in a country like China, where a significant elderly population is prevalent. In contrast, injectables are increasingly significant as they often provide more direct and immediate therapeutic effects, particularly in severe cases of AMD.As healthcare infrastructure improves in urban centers across China, the integration of advanced injectable therapies is expected to gain momentum, thereby addressing varying degrees of disease severity effectively. 

The trend is driven by the increasing prevalence of AMD due to an aging population and lifestyle factors, leading to a growing demand for effective treatment options. Opportunities in research and development for delivering more targeted therapies through both routes are on the rise, reflecting a shift toward precision medicine. However, challenges such as the need for skilled personnel to administer injectables and patient adherence to oral medications remain crucial considerations in realizing market potential in both pathways.

Dry Age-Related Macular Degeneration (AMD) Market End Users Insights

The End Users segment of the China Dry Age-Related Macular Degeneration (AMD) Market plays a critical role in addressing the growing needs of the population affected by AMD. As the prevalence of age-related eye conditions rises, hospitals clinics have become pivotal in providing essential diagnosis and treatment services. These facilities often have advanced medical technologies and personnel trained in retinal care, facilitating increased patient access to necessary therapies. Diagnostic centers are also crucial, offering specialized services that ensure early detection and accurate assessments, thus contributing significantly to managing AMD.Moreover, academic research institutes are instrumental in developing innovative treatments and conducting studies that advance the understanding of AMD.

Their findings are frequently disseminated, aiding healthcare providers in improving care protocols. The collaboration among these various end users not only enhances patient outcomes but also ensures a more integrated healthcare approach to managing dry AMD in China, reflecting the market's dynamic growth and response to evolving healthcare demands.

China Dry Age-Related Macular Degeneration (AMD) Market Key Players and Competitive Insights

The China Dry Age-Related Macular Degeneration (AMD) Market is rapidly evolving, influenced by various factors such as an aging population, increasing healthcare expenditure, and advancements in medical technology. Competitive insights in this market indicate a diverse landscape comprising both local and international players striving to capture market share with innovative treatment options for AMD. The market dynamics are characterized by a focus on drug development, clinical research, and regulatory approvals, all of which determine market positioning and competitiveness. 

Strategic partnerships and collaborations are becoming more common as companies look to leverage technological advancements and combine expertise in developing effective solutions for patients suffering from AMD. Understanding these competitive forces is crucial for companies aiming to establish a robust presence within the Chinese market.Bayer stands out as a key player in the China Dry Age-Related Macular Degeneration (AMD) Market, leveraging its extensive experience in the pharmaceutical sector. 

The company has established a strong market presence through its commitment to research and development, resulting in a portfolio of products that address the needs of AMD patients. Bayer's strengths include its robust distribution channels, strong brand reputation, and strategic partnerships that enhance its capability to deliver effective treatments to the Chinese market. 

Furthermore, Bayer has invested significantly in raising awareness and educating healthcare providers about AMD, which contributes to its competitive edge and positions the company favorably in a growing market.Horizon Therapeutics has also made significant inroads into the China Dry Age-Related Macular Degeneration (AMD) Market, focusing on innovative therapies that cater specifically to the needs of AMD patients. The company is known for its commitment to research and development and offers key products tailored to combat the challenges posed by dry AMD. With a growing market presence, Horizon Therapeutics is characterized by its strategic collaborations aimed at expanding its reach and enhancing its therapeutic offerings. 

The company has engaged in mergers and acquisitions to strengthen its portfolio and enhance its competencies. Horizon Therapeutics’ strengths lie in its ability to adapt to the unique requirements of the Chinese healthcare system while actively promoting education and awareness initiatives to further solidify its position in the China AMD market.

Key Companies in the China Dry Age-Related Macular Degeneration (AMD) Market Include:

• Bayer


• Horizon Therapeutics


• Zymeworks


• Ginkgo BioWorks


• Valeant Pharmaceuticals


• Bristol-Myers Squibb


• Roche


• Athenex


• Alcon


• Pfizer


• Novartis


• Santen Pharmaceutical


• Eyenovia


• Regeneron Pharmaceuticals

China Dry Age-Related Macular Degeneration (AMD) Market Industry Developments

In recent months, the China Dry Age-Related Macular Degeneration (AMD) Market has witnessed significant developments, particularly in advancements in treatment and drug approvals. Notably, companies like Regeneron Pharmaceuticals have been focusing on enhancing their product portfolios aimed at managing AMD, which remains a growing concern due to China's aging population. The market has been bolstered by new studies and clinical trials demonstrating the effectiveness of novel therapies. 

Furthermore, mergers and acquisitions have been a notable trend; for example, in August 2023, Bayer acquired a Chinese biotech firm specializing in retinal diseases, which aims to strengthen its foothold in the AMD sector. Growth in the market valuation has been increasingly influenced by heightened competition among major players such as Roche, Novartis, and Alcon, all actively engaging in innovative treatment research. 

The regulatory environment in China has also evolved, with the National Medical Products Administration accelerating the approval process for AMD treatments. This has fostered a more dynamic market landscape, enhancing accessibility for patients facing AMD. In the past two years, significant funding initiatives by the Chinese government to combat visual impairment diseases have further driven market expansion and research investment.

China Dry Age-Related Macular Degeneration (AMD) Market Segmentation Insights

• Dry Age-Related Macular Degeneration (AMD) Market Stage Outlook
  
  
  
  • Early Age-Related Macular Degeneration
  
  
  • Intermediate Age-Related Macular Degeneration
  
  
  • Late Age-Related Macular Degeneration
  
  
  
  

• Dry Age-Related Macular Degeneration (AMD) Market Age Group Outlook
  
  
  
  • Above 75 years
  
  
  • Above 60 years
  
  
  • Above 40 years
  
  
  
  

• Dry Age-Related Macular Degeneration (AMD) Market Diagnosis and Treatment Outlook
  
  
  
  • Treatment
  
  
  • Diagnosis
  
  
  
  

• Dry Age-Related Macular Degeneration (AMD) Market Route of Administration Outlook
  
  
  
  • Oral
  
  
  • Injectables
  
  
  
  

• 
  

  Dry Age-Related Macular Degeneration (AMD) Market End Users Outlook

  
  
  
  
  • 
    

    Hospitals Clinics

    
    
  
  
  • 
    

    Diagnostic Centers

    
    
  
  
  • 
    

    Academic Research Institutes

    
    
  
  
  
  

Report Attribute/Metric Source:	Details
MARKET SIZE 2023	330.0(USD Million)
MARKET SIZE 2024	360.0(USD Million)
MARKET SIZE 2035	910.0(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR)	8.796% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
MARKET FORECAST PERIOD	2025 - 2035
HISTORICAL DATA	2019 - 2024
MARKET FORECAST UNITS	USD Million
KEY COMPANIES PROFILED	Bayer, Horizon Therapeutics, Zymeworks, Ginkgo BioWorks, Valeant Pharmaceuticals, BristolMyers Squibb, Roche, Athenex, Alcon, Pfizer, Novartis, Santen Pharmaceutical, Eyenovia, Regeneron Pharmaceuticals
SEGMENTS COVERED	Stage, Age Group, Diagnosis and Treatment, Route of Administration, End Users
KEY MARKET OPPORTUNITIES	Increasing geriatric population, Rising healthcare expenditure, Growing awareness and diagnosis, Advancements in treatment options, Expanding telemedicine services
KEY MARKET DYNAMICS	aging population, increasing prevalence rates, rising healthcare expenditure, advancements in treatment options, growing awareness initiatives
COUNTRIES COVERED	China